Medical use of marijuana
DOI:
https://doi.org/10.35954/SM2017.36.2.4Keywords:
cannabinoids, endocannabinoids, medical marijuanaAbstract
The discovery of an endogenous cannabinoid system renewed medical interest in marijuana, and data in recent years indicate that the cannabinoid data in recent years indicate that the endocannobinoid endocannobinoid system regulates the function of various types of synapses and
synapses and plays an important role in extrauterine brain development. extrauterine brain development. Recently, interest in marijuana has focused on its recently focused on its medicinal properties, and there are controlled There are controlled clinical trials that support its use in certain in certain medical conditions; however, its efficacy and safety remain controversial.
In most of the studies evaluated in this review, the most prominent uses are in chronic oncologic and non-oncologic pain, nausea and vomiting. and non-oncologic chronic pain, nausea and vomiting due to chemotherapy, Cachexia associated with Acquired Immune Deficiency Syndrome, glaucoma Acquired Immune Deficiency Syndrome, glaucoma, Alzheimer's disease, Parkinson's disease, multiple sclerosis, spasticity and refractory epilepsy.
Translated with www.DeepL.com/Translator (free version)
Downloads
Metrics
References
(1) Contreras C, Gutiérrez-García A, Saavedra M, Bernal-Morales B, Rodríguez-Landa JF, HernándezLozano M. Efectos adversos y paliativos de los cannabinoides. Salud Mental 2003; 26(6):62-75.
(2) Rodríguez Carranza R. Los productos de Cannabis sativa: situación actual y perspectivas en medicina. Salud Mental 2012; 35(3):247-56.
(3) Covarrubias-Gomez A. Utilidad de la Cannabis sp. en medicina: una perspectiva basada en la historia. Rev Mex de Anest 2011; 34(2):138-40.
(4) Muñoz E. Cannabis en el tratamiento del dolor crónico no oncológico. Rev Hosp Clin Univ Chile 2015; 26(2):138-47.
(5) Vargas-Schaffer G. Aporte de los cannabinoides en el alivio del dolor neuropático. En: Gálvez Mateos R. Manual práctico del dolor neuropático. Barcelona : Elsevier, 2010. p.157-166.
(6) Deshpande A, Mailis-Gagnon A, Zoheiry N, Lakha SF. Efficacy and adverse effects of medical marijuana for chronic noncancer pain: Systematic review of randomized controlled trials. Can Fam Physician 2015; 61(8):e372-81.
(7) Torres LM, Trinidad JM, Calderón E. Potencial terapéutico de los cannabinoides. Rev Soc Esp Dolor 2013; 20(3):132-36.
(8) De Vries TJ, Shaham Y, Homberg JR, Crombag H, Schuurman K, Dieben J, et al. Acannabinoid mechanism in relapse to cocaine seeking. Nat Med 2001; 7(10):1151-4.
(9) Fattore L, Martellotta MC, Cossu G, Mascia MS, Fratta W. CB1 cannabinoid receptor agonist WIN55, 212-2 decreases intravenous cocaine self administration in rats. Behav Brain Res 1999; 104(1-2):141-8.
(10) Kahan M, Srivastava A, Spithoff S, Bromley L. Prescribing smoked cannabis for chronic noncancer pain: preliminary recommendations. Can Fam Physician 2014; 60(12):1083-90.
(11) Tramer MR, Carroll D, Campbell FA, Reynols DJ, Moore RA, McQuay HJ. Cannabis control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001; 323(7303):16-21.
(12) Aso E, Ferrer I. Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic. Front Pharmacol 2014; 5:37.
(13) Carter G, Ugalde V. Medical marijuana: emerging applications for the management of neurologic disorders. Phys Med Rehabil Clin N Am 2004; 15(4):943-54.ix.
(14) Van den Elsen G, Ahmed A, Verkes R, Kramers C, Feuth T, Rosenberg P, et al. Tetrahydrocannabinol for neuropsiychiatric symtoms in dementia. A randomized controlled trial. Neurology 2015; 84(23):2338-46.
(15) Jimenez-Jimenez FJ, Alonso-Navarro H, Luquin Piudo MR, Burguera Hernandez JA. Trastornos del movimiento (I): conceptos generales, clasificación de los síndromes parkinsonianos y enfermedad de Parkinson. Medicine 2015; 11(74):4415-26.
(16) Saito VM, Rezende RM, Texeira AL. Cannabinoid modulation of neuroinflammatory disorders. Curr Neuropharmacol 2012; 10(2):159-66.
(17) Kluger B, Triolo P, Jones W, Jankovic J. The therapeutic potential of Cannabinoids for movement disorders. Mov Disord 2015; 30(3):313-327.
(18) Grandes Moreno P. Sistema endocannabinoide. En:Zarranz JJ (Ed.).Neurofarmacologia contemporanea. Barcelona : Elsevier, 2011. p.301-24.
(19) Fife T, Heidi M, Moschonas C, Shepard K, Hammond N. Clinical perspectives on medical marijuana (cannabis) for neurologic disorder. Neurol Clin Pract 2015; 5(4):344-351.
(20) Alexander S. Therapeutic potential of cannabisrelated drugs.Prog Neuro-phychopharmacol biol psychiatry 2016; 64:157-166.
(21) Pinar-Sueiro S, Rodríguez-Puertas R, Vecino E. Aplicaciones de los cannabinoides en glaucoma. Arch Soc Esp Oftalmol 2011; 86(1):16-23.
(22) Zozaya Aldana B, Medina Rodríguez I, Tamayo Pineda N. Cannabinoides y su posible uso en el glaucoma. Rev Cubana Far 2011; 45(3):439-48.
(23) Bonfá L, Contreiras de Oliveira R, Verçosa de Figueiredo N. Uso de canabinóides na dor crônica e em Cuidados Paliativos. Rev Bras Anestesiol 2008; 58(3):267-79.
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Marta Hatchondo, Laura Pegueroles, Marcela Quintana. The author retains his copyright and assigns to the journal the right of first publication of his work, which will be simultaneously subject to the Creative Commons Attribution 4.0 International License that allows sharing the work as long as the initial publication in this journal is indicated.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Until 2024 we use the Creative Commons Attribution/NonCommercial Attribution 4.0 International License https://creativecommons.org/licenses/by-nc/4.0/deed.es. Which states that: you are free to share, copy and redistribute the material in any medium or format, as well as to adapt, remix, transform and build upon the material. Under the following terms:
Attribution: you must give proper credit , provide a link to the license, and indicate if changes have been made . You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
NonCommercial: you may not use the material for commercial purposes.
As of 2025 authors retain their copyright and assign to the journal the right of first publication of their work, which shall simultaneously be subject to the license https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es that permits sharing, copying and redistribution of the material in any medium or format provided that initial publication in this journal is indicated. Adapt, remix, transform and build upon the material. If you remix, transform, or build from the material, you must distribute your contribution under the same license as the original and may not make use of the material for commercial purposes.
Under the following terms:
1. Attribution: you must give proper credit, provide a link to the license, and indicate whether changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
2. NonCommercial: you may not use the material for commercial purposes.
3. ShareAlike: if you remix, transform or build upon the material, you must distribute your contribution under the same license as the original.
PlumX Metrics
/
